Marqibo FDA Approval History
FDA Approved: Yes (First approved August 9, 2012)
Brand name: Marqibo
Generic name: vincristine sulfate liposomes
Dosage form: Injection
Previous Name: Onco TCS
Company: Talon Therapeutics Inc.
Treatment for: Acute Lymphoblastic Leukemia
Marqibo (vincristine sulfate liposome injection) is a vinca alkaloid indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
Development Timeline for Marqibo
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.